Alimera Sciences is a research and development company. Serving the medical field, its areas of development include diabetic retinopathy, age-related macular degeneration, retinal vein occlusion and diabetic macular edema (DME). Its principal products are the proposed pharmaceutical treatment ILUVIEN for DME and NADPH oxidase inhibitors. Its president is Dan Myers.